Low-dose caffeine discrimination in humans

Roland R Griffiths, S. M. Evans, S. J. Heishman, K. L. Preston, C. A. Sannerud, B. Wolf, P. P. Woodson

Research output: Contribution to journalArticle

Abstract

A novel drug discrimination procedure was used to study the discriminability and subjective effects of caffeine in seven human volunteers who abstained from dietary sources of caffeine. Daily sessions involved p.o. ingestion of two capsules sequentially, one of which contained caffeine and the other placebo, under double-blind conditions. Each day subjects attempted to identify and were later informed which capsule contained caffeine and which contained placebo. All subjects acquired rapidly the initial discrimination (100 or 178 mg vs. placebo). Examination of progressively lower caffeine doses showed that accuracy and ratings of confidence in accuracy were increasing functions of dose. There were individual differences in the lowest discriminable dose: three subjects discriminated 56 mg, three discriminated 18 mg and one discriminated 10 mg. Discrimination accuracy was usually higher after the second capsule than after the first capsule. All subjects indicated that they believed that they made the discrimination predominantly on the basis of central effects of caffeine vs. placebo, such as changes in mood and socializing. Compared to placebo, 100 mg of caffeine increased ratings of alertness, well-being, social disposition, motivation for work, concentration, energy and self-confidence and decreased ratings of headache and sleepiness. This dose of caffeine also produced a large increase in a measure of 'euphoria'. The present study documents biological activity of caffeine at lower doses than heretofore recognized. The general approach to investigating the effects of low drug doses may have broad application in human psychopharmacology research for characterizing other subtle psychotropic effects.

Original languageEnglish (US)
Pages (from-to)970-978
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume252
Issue number3
StatePublished - 1990

Fingerprint

Caffeine
Placebos
Capsules
Psychopharmacology
Individuality
Pharmaceutical Preparations
Headache
Motivation
Volunteers
Eating
Research

ASJC Scopus subject areas

  • Pharmacology

Cite this

Griffiths, R. R., Evans, S. M., Heishman, S. J., Preston, K. L., Sannerud, C. A., Wolf, B., & Woodson, P. P. (1990). Low-dose caffeine discrimination in humans. Journal of Pharmacology and Experimental Therapeutics, 252(3), 970-978.

Low-dose caffeine discrimination in humans. / Griffiths, Roland R; Evans, S. M.; Heishman, S. J.; Preston, K. L.; Sannerud, C. A.; Wolf, B.; Woodson, P. P.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 252, No. 3, 1990, p. 970-978.

Research output: Contribution to journalArticle

Griffiths, RR, Evans, SM, Heishman, SJ, Preston, KL, Sannerud, CA, Wolf, B & Woodson, PP 1990, 'Low-dose caffeine discrimination in humans', Journal of Pharmacology and Experimental Therapeutics, vol. 252, no. 3, pp. 970-978.
Griffiths RR, Evans SM, Heishman SJ, Preston KL, Sannerud CA, Wolf B et al. Low-dose caffeine discrimination in humans. Journal of Pharmacology and Experimental Therapeutics. 1990;252(3):970-978.
Griffiths, Roland R ; Evans, S. M. ; Heishman, S. J. ; Preston, K. L. ; Sannerud, C. A. ; Wolf, B. ; Woodson, P. P. / Low-dose caffeine discrimination in humans. In: Journal of Pharmacology and Experimental Therapeutics. 1990 ; Vol. 252, No. 3. pp. 970-978.
@article{fba61bfe822448e6834cc04ea2a4b6e4,
title = "Low-dose caffeine discrimination in humans",
abstract = "A novel drug discrimination procedure was used to study the discriminability and subjective effects of caffeine in seven human volunteers who abstained from dietary sources of caffeine. Daily sessions involved p.o. ingestion of two capsules sequentially, one of which contained caffeine and the other placebo, under double-blind conditions. Each day subjects attempted to identify and were later informed which capsule contained caffeine and which contained placebo. All subjects acquired rapidly the initial discrimination (100 or 178 mg vs. placebo). Examination of progressively lower caffeine doses showed that accuracy and ratings of confidence in accuracy were increasing functions of dose. There were individual differences in the lowest discriminable dose: three subjects discriminated 56 mg, three discriminated 18 mg and one discriminated 10 mg. Discrimination accuracy was usually higher after the second capsule than after the first capsule. All subjects indicated that they believed that they made the discrimination predominantly on the basis of central effects of caffeine vs. placebo, such as changes in mood and socializing. Compared to placebo, 100 mg of caffeine increased ratings of alertness, well-being, social disposition, motivation for work, concentration, energy and self-confidence and decreased ratings of headache and sleepiness. This dose of caffeine also produced a large increase in a measure of 'euphoria'. The present study documents biological activity of caffeine at lower doses than heretofore recognized. The general approach to investigating the effects of low drug doses may have broad application in human psychopharmacology research for characterizing other subtle psychotropic effects.",
author = "Griffiths, {Roland R} and Evans, {S. M.} and Heishman, {S. J.} and Preston, {K. L.} and Sannerud, {C. A.} and B. Wolf and Woodson, {P. P.}",
year = "1990",
language = "English (US)",
volume = "252",
pages = "970--978",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - Low-dose caffeine discrimination in humans

AU - Griffiths, Roland R

AU - Evans, S. M.

AU - Heishman, S. J.

AU - Preston, K. L.

AU - Sannerud, C. A.

AU - Wolf, B.

AU - Woodson, P. P.

PY - 1990

Y1 - 1990

N2 - A novel drug discrimination procedure was used to study the discriminability and subjective effects of caffeine in seven human volunteers who abstained from dietary sources of caffeine. Daily sessions involved p.o. ingestion of two capsules sequentially, one of which contained caffeine and the other placebo, under double-blind conditions. Each day subjects attempted to identify and were later informed which capsule contained caffeine and which contained placebo. All subjects acquired rapidly the initial discrimination (100 or 178 mg vs. placebo). Examination of progressively lower caffeine doses showed that accuracy and ratings of confidence in accuracy were increasing functions of dose. There were individual differences in the lowest discriminable dose: three subjects discriminated 56 mg, three discriminated 18 mg and one discriminated 10 mg. Discrimination accuracy was usually higher after the second capsule than after the first capsule. All subjects indicated that they believed that they made the discrimination predominantly on the basis of central effects of caffeine vs. placebo, such as changes in mood and socializing. Compared to placebo, 100 mg of caffeine increased ratings of alertness, well-being, social disposition, motivation for work, concentration, energy and self-confidence and decreased ratings of headache and sleepiness. This dose of caffeine also produced a large increase in a measure of 'euphoria'. The present study documents biological activity of caffeine at lower doses than heretofore recognized. The general approach to investigating the effects of low drug doses may have broad application in human psychopharmacology research for characterizing other subtle psychotropic effects.

AB - A novel drug discrimination procedure was used to study the discriminability and subjective effects of caffeine in seven human volunteers who abstained from dietary sources of caffeine. Daily sessions involved p.o. ingestion of two capsules sequentially, one of which contained caffeine and the other placebo, under double-blind conditions. Each day subjects attempted to identify and were later informed which capsule contained caffeine and which contained placebo. All subjects acquired rapidly the initial discrimination (100 or 178 mg vs. placebo). Examination of progressively lower caffeine doses showed that accuracy and ratings of confidence in accuracy were increasing functions of dose. There were individual differences in the lowest discriminable dose: three subjects discriminated 56 mg, three discriminated 18 mg and one discriminated 10 mg. Discrimination accuracy was usually higher after the second capsule than after the first capsule. All subjects indicated that they believed that they made the discrimination predominantly on the basis of central effects of caffeine vs. placebo, such as changes in mood and socializing. Compared to placebo, 100 mg of caffeine increased ratings of alertness, well-being, social disposition, motivation for work, concentration, energy and self-confidence and decreased ratings of headache and sleepiness. This dose of caffeine also produced a large increase in a measure of 'euphoria'. The present study documents biological activity of caffeine at lower doses than heretofore recognized. The general approach to investigating the effects of low drug doses may have broad application in human psychopharmacology research for characterizing other subtle psychotropic effects.

UR - http://www.scopus.com/inward/record.url?scp=0025257435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025257435&partnerID=8YFLogxK

M3 - Article

C2 - 2319479

AN - SCOPUS:0025257435

VL - 252

SP - 970

EP - 978

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -